[Number 1.1 Circular regarding proposed amendments to Articles of Association and notice of extraordinary general meeting, dated November 3, 2017 6-K our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans]
[Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq BEIJING, November 3, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(”Sinovac”), a leading provider of biopharmaceutical products in China, announced today that on November 1, 2017, the Company received a delisti]
[Number 1.1 Circular regarding proposed amendments to Articles of Association and notice of extraordinary general meeting, dated November 3, 2017 6-K our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans]
[Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq BEIJING, November 3, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(”Sinovac”), a leading provider of biopharmaceutical products in China, announced today that on November 1, 2017, the Company received a delisti]
